HIV / AIDS

One month after the Food and Drug Administration (FDA) approval of monthly rilpivirine/cabotegravir (Cabenuva) for HIV, Janssen has submitted evidence of efficacy with dosing every 2 months.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.

A John Hopkins expert and major study leader details the evolving epidemiology of the virus.

HIV-associated wasting remains common complication despite treatment with antiretroviral therapy.

Ruth Coker Burks’ new book, All the Young Men, chronicles her years at the bedside of victims.

HIV testing and initiation of antiretroviral therapy (ART) fell in South Africa during the national lockdown in response to the coronavirus disease 2019 (COVID-19) pandemic, a new study shows.

Derek Blechinger, MD, MPH, and a team at the Kaiser Permanente San Francisco Medical Center have developed an HIV prediction model to find patients earlier in the care cycle who could benefit from pre-exposure prophylaxis (PrEP) therapy.

Educating young people is especially critical and many countries have seen great success in youth education as a prevention strategy.

A syndemic association between the two infections may have an increasing impact on affected people and communities.

Among people living with HIV, lower white blood cell counts were associated with smaller brain volume in the hippocampus and thalamus, a new study found, suggesting the possibility of generalizable neurologic signatures of HIV infections.

The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.

A study found patients with acute infection and those with viral rebound after antiretroviral therapy interruption had the highest viral resistance to type 1 interferons.

Anal squamous cell carcinoma mortality rate is rising faster than other types of cancer in the United States.

While social determinants, stigma about the virus, and continuum of care issues remain challenges to many people with HIV, The IDSA is looking to address these issues with its new guidance.

The FDA’s breakthrough designation of cabotegravir along with adaptive strategies being deployed are the biggest stories in HIV prevention this year.

A principal investigator studying dolutegravir/lamivudine discusses its efficacy and potential treatment benefits.

A research team recently presented their efforts to integrate machine learning to identify people at high-risk of acquiring HIV.

A new article shows that breastfeeding after receiving dolutegravir in late pregnancy contributed relatively little infant plasma exposure but additional prophylaxis was reported among some.

The ADVANCE study results at 96 weeks distinguish between the long-term effects of 3 combination regimens for HIV in weight gain and bone density change.

Participants in clinical trials of long-acting injectable antiretroviral therapy for HIV describe expectations and experience with the investigational dosage form.

An expert panel discussion around long-acting injectables' role in both preventing and treating HIV.

Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.

Modulating gut microbiota could have therapeutic benefits for people living with HIV, according to a recent study that found HIV infection in women was associated with altered gut microbiota and distinct plasma metabolite profile.

New data sheds light on efficacy of longer periods between dosing.

Antiviral therapy that suppresses HIV-1 viremia does not block release of cell-associated RNA after infection or the inflammatory response it provokes.

The HIV Policy Lab report examined which countries are adopting laws endorsed by various international agencies in the fight against AIDS.

The Aptima HIV-1 Quant Dx assay is the first in the US to be able to make such a claim.